Granted Patent B2

US 12,516,044 · App. 17/125,624 · Granted Jan 6, 2026

Inventors: Liangxing Wu (Wilmington, DE); Zhiyong Yu (Wilmington, DE); Fenglei Zhang (Berwyn, PA); Wenqing Yao (Chadds Ford, PA)

Assignee: Incyte Corporation

C07D413/12C07D213/81C07D213/84C07D237/24C07D239/28C07D241/24C07D401/06C07D401/12C07D401/14C07D405/12C07D405/14

Abstract

Claims (91)

1 . A compound having Formula (II):

or a pharmaceutically acceptable salt thereof, wherein:

X 1 is CR 1 ;

X 3 is N or CR 3 ;

X 4 is N or CR 4 ;

R 1 , R 3 , and R 4 are each independently selected from H, halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 6-10 aryl, C 3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-4 alkyl-, C 3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, CN, NO 2 , OR a , SR a , NHOR a , C(O)R a , C(O)NR a R a , C(O)OR a , OC(O)R a , OC(O)NR a R a , NHR a , NR a R a , NR a C(O)R a , NR a C(O)OR a , NR a C(O)NR a R a , C(═NR a )R a , C(═NR a )NR a R a , NR a C(═NR a )NR a R a , NR a S(O)R a , NR a S(O) 2 R a , NR a S(O) 2 NR a R a , S(O)R a , S(O)NR a R a , S(O) 2 R a , and S(O) 2 NR a R a , wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 aryl, C 3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-4 alkyl-, C 3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-C 1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of R 1 , R 3 , and R 4 are each optionally substituted with 1, 2, 3, or 4 R b substituents;

R 2 is halo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 6-10 aryl, C 3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-4 alkyl-, C 3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, CN, NO 2 , OR a , SR a , NHOR a , C(O)R a , C(O)NR a R a , C(O)OR a , OC(O)R a , OC(O)NR a R a , NHR a , NR a R a , NR a C(O)R a , NR a C(O)OR a , NR a C(O)NR a R a , C(═NR a )R a , C(═NR a )NR a R a , NR a C(═NR a )NR a R a , NR a S(O)R a , NR a S(O) 2 R a , NR a S(O) 2 NR a R a , S(O)R a , S(O)NR a R a , S(O) 2 R a , and S(O) 2 NR a R a , wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-14 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-4 alkyl-, C 3-10 cycloalkyl-C 1-4 alkyl-, (5-14 membered heteroaryl)-C 1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of R 2 are each optionally substituted with 1, 2, 3, or 4 R b substituents;

each R 7 is H, or, alternatively, two adjacent R 7 's, taken together with the carbon atoms to which they are attached, form a fused phenyl ring, a fused 5- to 7-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C 5-6 cycloalkyl ring, wherein the fused 5- to 7-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5- to 7-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C 3-10 cycloalkyl ring are each optionally substituted with 1 or 2 independently selected R Q substituents;

R 5 is CH 3 or CN;

each R 6 is independently selected from H, halo, CN, and CH 3 ;

or R 2 and X 1 taken together form a fused phenyl ring, a fused 4- to 10-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C 3-10 cycloalkyl ring, wherein the fused 4- to 10-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5- or 6-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C 5-6 cycloalkyl ring are each optionally substituted with 1 or 2 independently selected R b substituents;

or R 2 and X 3 taken together form a fused phenyl ring, a fused 4- to 10-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C 3-10 cycloalkyl ring, wherein the fused 4- to 10-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5- or 6-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C 5-6 cycloalkyl ring are each optionally substituted with 1 or 2 independently selected R b substituents;

or R 3 and X 4 taken together form a fused phenyl ring, a fused 4- to 10-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C 3-10 cycloalkyl ring, wherein the fused 4- to 10-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5- or 6-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C 5-6 cycloalkyl ring are each optionally substituted with 1 or 2 independently selected R b substituents;

or R 4 and X 3 taken together form a fused phenyl ring, a fused 4- to 10-membered heterocycloalkyl ring, a fused 5- or 6-membered heteroaryl ring or a fused C 3-10 cycloalkyl ring, wherein the fused 4- to 10-membered heterocycloalkyl ring and fused 5- or 6-membered heteroaryl ring each have 1-4 heteroatoms as ring members selected from N, O and S and wherein the fused phenyl ring, fused 5- or 6-membered heterocycloalkyl ring, fused 5- or 6-membered heteroaryl ring and fused C 5-6 cycloalkyl ring are each optionally substituted with 1 or 2 independently selected R b substituents;

each R a is independently selected from H, CN, C 1-6 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, C 2-4 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-4 alkyl-, C 3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-4 alkyl-, C 3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl- and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of R a are each optionally substituted with 1, 2, 3, 4, or 5 R d substituents;

each R d is independently selected from C 1-4 alkyl, C 1-4 haloalkyl, halo, C 3-10 cycloalkyl, 4-10 membered heterocycloalkyl, CN, NH 2 , NHOR e , OR e , SR e , C(O)R e , C(O)NR e R e , C(O)OR e , OC(O)R e , OC(O)NR e R e , NHR e , NR e R e , NR e C(O)R e , NR e C(O)NR e R e , NR e C(O)OR e , C(═NR e )NR e R e , NR e C(═NR e )NR e R e , S(O)R e , S(O)NR e R e , S(O) 2 R e , NR e S(O) 2 R e , NR e S(O) 2 NR e R e , and S(O) 2 NR e R e , wherein the C 1-4 alkyl, C 3-10 cycloalkyl and 4-10 membered heterocycloalkyl of R d are each further optionally substituted with 1-3 independently selected R q substituents;

each R b substituent is independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-4 alkyl-, C 3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, CN, OH, NH 2 , NO 2 , NHOR c , OR c , SR c , C(O)R c , C(O)NR c R c , C(O)OR c , OC(O)R c , OC(O)NR c R c , C(═NR c )NR c R c , NR c C(═NR c )N c R c , NHR c , NR c R c , NR c C(O)R c , NR c C(O)OR c , NR c C(O)NR c R c , NR c S(O)R c , NR c S(O) 2 R c , NR c S(O) 2 NR c R c , S(O)R c , S(O)NR c R c , S(O) 2 R c and S(O) 2 NR c R c ; wherein the C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-4 alkyl-, C 3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl- and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of R b are each further optionally substituted with 1-3 independently selected R d substituents;

each R c is independently selected from H, C 1-6 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-4 alkyl-, C 3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-4 alkyl-, C 3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl- and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of R c are each optionally substituted with 1, 2, 3, 4, or 5 R f substituents;

each R f is independently selected from C 1-4 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-4 alkyl-, C 3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, halo, CN, NHOR g , OR g , SR g , C(O)R g , C(O)NR g R g , C(O)OR g , OC(O)R g , OC(O)NR g R g , NHR g , NR g R g , NR g C(O)R g , NR g C(O)NR g R g , NR g C(O)OR g , C(═NR g )NR g R g , NR g C(═NR g )NR g R g , S(O)R g , S(O)NR g R g , S(O) 2 R g , NR g S(O) 2 R g , NR g S(O) 2 NR g R g , and S(O) 2 NR g R g ; wherein the C 1-4 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-4 alkyl-, C 3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of R f are each optionally substituted with 1, 2, 3, 4, or 5 R n substituents;

each R n is independently selected from C 1-4 alkyl, C 1-4 haloalkyl, halo, CN, R o , NHOR o , OR o , SR o , C(O)R o , C(O)NR o R o , C(O)OR o , OC(O)R o , OC(O)NR o R o , NHR o , NR o R o , NR o C(O)R o , NR o C(O)NR o R o , NR o C(O)OR o , C(═NR o )NR o R o , NR o C(═NR o )NR o R o , S(O)R o , S(O)NR o R o , S(O) 2 R o , NR o S(O) 2 R o , NR o S(O) 2 NR o R o , and S(O) 2 NR o R o ;

each R g is independently selected from H, C 1-6 alkyl, C 1-4 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-4 alkyl-, C 3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl-, and (4-10 membered heterocycloalkyl)-C 1-4 alkyl-, wherein the C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C 6-10 aryl-C 1-4 alkyl-, C 3-10 cycloalkyl-C 1-4 alkyl-, (5-10 membered heteroaryl)-C 1-4 alkyl- and (4-10 membered heterocycloalkyl)-C 1-4 alkyl- of R g are each optionally substituted with 1-3 independently selected R p substituents;

or any two R a substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 R h substituents;

each R h is independently selected from C 1-6 alkyl, C 3-10 cycloalkyl, 4-7 membered heterocycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-C 1-4 alkyl-, (4-7 membered heterocycloalkyl)-C 1-4 alkyl-, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo, CN, OR i , SR i , NHOR i , C(O)R i , C(O)NR i R i , C(O)OR i , OC(O)R i , OC(O)NR i R i , NHR i , NR i R i , NR i C(O)R i , NR i C(O)NR i R i , NR i C(O)OR i , C(═NR i )NR i R i , NR i C(═NR i )NR i R i , S(O)R i , S(O)NR i R i , S(O) 2 R, NR i S(O) 2 R i , NR i S(O) 2 NR i R i , and S(O) 2 NR i R i , wherein the C 1-6 alkyl, C 3-10 cycloalkyl, 4-7 membered heterocycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl-, (5-6 membered heteroaryl)-C 1-4 alkyl-, and (4-7 membered heterocycloalkyl)-C 1-4 alkyl- of R h are each further optionally substituted by 1, 2, or 3 R j substituents;

each R j is independently selected from C 3-6 cycloalkyl, C 6-10 aryl, 5 or 6-membered heteroaryl, C 2-4 alkenyl, C 2-4 alkynyl, halo, C 1-4 alkyl, C 1-4 haloalkyl, CN, NHOR k , OR k , SR k , C(O)R k , C(O)NR k R k , C(O)OR k , OC(O)R k , OC(O)NR k R k , NHR k , N k R k , NR k C(O)R k , NR k C(O)NR k R k , NR k C(O)OR k , C(═NR k k)NR k R k k, NR k C(═NR k k)NR k R k k, S(O)R k , S(O)NR k R k , S(O) 2 R k , NRWS(O) 2 R k , NR k S(O) 2 NR k R k , and S(O) 2 NR k R k ;

or two R h groups attached to the same carbon atom of the 4- to 10-membered heterocycloalkyl taken together with the carbon atom to which they are attached form a C 3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl having 1-2 heteroatoms as ring members selected from O, N or S;

or any two R c substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;

or any two R e substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;

or any two R g substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;

or any two R o substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents; and

each R e , R i , R k , R o or R p is independently selected from H, C 1-4 alkyl, C 3-6 cycloalkyl, C 6-10 aryl, 5 or 6-membered heteroaryl, C 1-4 haloalkyl, C 2-4 alkenyl, and C 2-4 alkynyl, wherein the C 1-4 alkyl, C 3-6 cycloalkyl, C 6-10 aryl, 5 or 6-membered heteroaryl, C 2-4 alkenyl, and C 2-4 alkynyl of R e , R i , R k , R o or R p are each optionally substituted with 1, 2 or 3 R q substituents;

each R q is independently selected from OH, CN, —COOH, NH 2 , halo, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, phenyl, 5-6 membered heteroaryl, C 3-6 cycloalkyl, NHR 8 , NR 8 R 8 , and C 1-4 haloalkoxy, wherein the C 1-4 alkyl, phenyl and 5-6 membered heteroaryl of R q are each optionally substituted with OH, CN, —COOH, NH 2 , C 1-4 alkoxy, C 3-10 cycloalkyl and 4-, 5-, or 6-membered heterocycloalkyl;

each R 8 is independently C 1-6 alkyl;

the subscript n is an integer of 1, 2, 3, 4 or 5; and

the subscript m is an integer of 0.

2 . The compound of claim 1 , having Formula (III):

or a pharmaceutically acceptable salt thereof.

3 . The compound of claim 1 , having Formula (V):

or a pharmaceutically acceptable salt thereof.

4 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the moiety

is selected from:

5 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 3 is CR 3 and X 4 is CR 4 .

6 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 3 is N and X 4 is CR 4 .

7 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 3 is CR 3 and X 4 is N.

8 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 , R 3 and R 4 , when applicable, are each independently selected from H, C 1-6 alkyl and halo.

9 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is —CH 2 —R b .

10 . The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein R b is —CR c R c .

11 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is 2-hydroxyethylaminomethyl, 2-carboxypiperidin-1-ylmethyl, (S)-2-carboxypiperidin-1-ylmethyl, (R)-2-carboxypiperidin-1-ylmethyl or (3-cyanobenzyl)oxy.

12 . The compound of claim 1 , wherein the compound is selected from:

(2S)-1-[(6-{[(2-methylbiphenyl-3-yl)amino]carbonyl}pyridin-3-yl)methyl]piperidine-2-carboxylic acid;

5-{[(2-hydroxyethyl)amino]methyl}-N-(2-methylbiphenyl-3-yl)pyridine-2-carboxamide;

(2S)-1-[(5-methyl-6-{[(2-methylbiphenyl-3-yl)amino]carbonyl}pyridin-3-yl)methyl]piperidine-2-carboxylic acid;

5-{[(2-hydroxyethyl)amino]methyl}-3-methyl-N-(2-methylbiphenyl-3-yl)pyridine-2-carboxamide;

(2S)-1-[(2-{[(2-methylbiphenyl-3-yl)amino]carbonyl}pyrimidin-5-yl)methyl]piperidine-2-carboxylic acid;

5-{[(2-hydroxyethyl)amino]methyl}-N-(2-methylbiphenyl-3-yl)pyrimidine-2-carboxamide;

(2S)-1-[(6-{[(2-cyanobiphenyl-3-yl)amino]carbonyl}pyridin-3-yl)methyl]piperidine-2-carboxylic acid;

N-(2-cyanobiphenyl-3-yl)-5-{[(2-hydroxyethyl)amino]methyl}pyridine-2-carboxamide;

(2S)-1-{[6-{[2-cyano-3-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]amino}carbonyl)pyridin-3-yl]methyl}piperidine-2-carboxylic acid;

N-(2-cyano-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)phenyl)-5-((2-hydroxyethylamino)methyl)picolinamide;

5-{[(2-hydroxyethyl)amino]methyl}-N-(2-methylbiphenyl-3-yl)pyrazine-2-carboxamide;

(2S)-1-[(2-methyl-6-{[(2-methylbiphenyl-3-yl)amino]carbonyl}pyridin-3-yl)methyl]piperidine-2-carboxylic acid;

5-{[(2-hydroxyethyl)amino]methyl}-6-methyl-N-(2-methylbiphenyl-3-yl)pyridine-2-carboxamide;

(2S)-1-[(5-chloro-6-{[(2-methylbiphenyl-3-yl)amino]carbonyl}pyridin-3-yl)methyl]piperidine-2-carboxylic acid;

3-chloro-5-{[(2-hydroxyethyl)amino]methyl}-N-(2-methylbiphenyl-3-yl)pyridine-2-carboxamide;

3-fluoro-5-{[(2-hydroxyethyl)amino]methyl}-N-(2-methylbiphenyl-3-yl)pyridine-2-carboxamide;

4-[(3-cyanobenzyl)oxy]-5-{[(2-hydroxyethyl)amino]methyl}-N-(2-methylbiphenyl-3-yl)pyridine-2-carboxamide;

5-{[(2-hydroxyethyl)amino]methyl}-N-(2-methylbiphenyl-3-yl)-4-(pyridin-3-ylmethoxy)pyridine-2-carboxamide;

5-{[(2-hydroxyethyl)amino]methyl}-N-(2-methylbiphenyl-3-yl)-4-(pyridin-2-ylmethoxy)pyridine-2-carboxamide; and

3-(dimethylamino)-5-{[(2-hydroxyethyl)amino]methyl}-N-(2-methylbiphenyl-3-yl)pyridine-2-carboxamide;

or a pharmaceutically acceptable salt thereof.

13 . The compound of claim 1 , wherein the compound is selected from:

5-{[(2-hydroxyethyl)amino]methyl}-N-(2-methylbiphenyl-3-yl)-4,4′-bipyridine-2-carboxamide;

(2S)-1-[(4-methyl-6-{[(2-methylbiphenyl-3-yl)amino]carbonyl}pyridin-3-yl)methyl]piperidine-2-carboxylic acid;

5-{[(2-hydroxyethyl)amino]methyl}-4-methyl-N-(2-methylbiphenyl-3-yl)pyridine-2-carboxamide;

4-(cyclopropylmethoxy)-5-((2-hydroxyethylamino)methyl)-N-(2-methylbiphenyl-3-yl)picolinamide;

5-{[(2-hydroxyethyl)amino]methyl}-4-methoxy-N-(2-methylbiphenyl-3-yl)pyridine-2-carboxamide;

(2S)-1-[(5-methyl-2-{[(2-methylbiphenyl-3-yl)amino]carbonyl}pyridin-4-yl)methyl]piperidine-2-carboxylic acid;

4-{[(2-hydroxyethyl)amino]methyl}-5-methyl-N-(2-methylbiphenyl-3-yl)pyridine-2-carboxamide;

N-[2-cyano-3-(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)phenyl]-5-{[(2-hydroxyethyl)amino]methyl}pyridine-2-carboxamide;

N-[2-cyano-3-(2,3-dihydro-1-benzofuran-6-yl)phenyl]-5-{[(2-hydroxyethyl)amino]methyl}pyridine-2-carboxamide;

N-[2-cyano-3-(2-methyl-2H-indazol-6-yl)phenyl]-5-{[(2-hydroxyethyl)amino]methyl}pyridine-2-carboxamide; and

N-[2-cyano-3-(1-methyl-1H-indazol-4-yl)phenyl]-5-{[(2-hydroxyethyl)amino]methyl}pyridine-2-carboxamide;

or a pharmaceutically acceptable salt thereof.

14 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

15 . A method of inhibiting PD-1/PD-L1 interaction, said method comprising administering to a patient a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

16 . A method of treating a disease or disorder associated with PD-1/PD-L1 interaction, said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

17 . The method of claim 16 , wherein the disease or disorder is a viral infection.

18 . The method of claim 16 , wherein the disease or disorder is cancer.

19 . The method of claim 18 , wherein the cancer is selected from Ewing sarcoma, cholangiocarcinoma, bone cancer, pancreatic cancer, skin cancer, cancer of head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of anal region, stomach cancer, testicular cancer, carcinoma of fallopian tubes, carcinoma of endometrium, endometrial cancer, carcinoma of cervix, carcinoma of vagina, carcinoma of vulva, non-Hodgkin's lymphoma, cancer of esophagus, cancer of small intestine, cancer of endocrine system, cancer of thyroid gland, cancer of parathyroid gland, cancer of adrenal gland, sarcoma of soft tissue, cancer of urethra, cancer of penis, chronic or acute leukemias, solid tumors of childhood, lymphocytic lymphoma, cancer of bladder, carcinoma of renal pelvis, neoplasm of central nervous system (CNS), primary central nervous system (CNS) lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, cancers induced by asbestos, melanoma, metastatic malignant melanoma, renal cancer, renal clear cell carcinoma, prostate cancer, hormone refractory prostate adenocarcinoma, breast cancer, colon cancer, lung cancer, non-small cell lung cancer, solid tumors, hepatic cancer, gastric cancer, glioblastoma, sarcoma, hematological cancers, lymphoma, leukemia, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, relapsed or refractory non-Hodgkin lymphoma (NHL), recurrent follicular lymphoma, Hodgkin lymphoma and multiple myeloma.

20 . The method of claim 18 , wherein the cancer is selected from a metastatic cancer that expresses PD-L1, lung cancer, non-small cell lung cancer, hepatic cancer, melanoma, cancer of bladder, cancer of urethra, squamous cell cancer, renal cancer, and renal clear cell carcinoma.

21 . A method of enhancing, stimulating, modulating and/or increasing immune response in a patient, said method comprising administering to the patient in need thereof a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

22 . A method of inhibiting growth, proliferation, or metastasis of cancer cells in a patient, said method comprising administering to the patient in need thereof a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

Assignments (1)

Continuity (10)

References Cited (400)